Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine.

Widespread use of 7-valent pneumococcal conjugate vaccine (PCV7) has led to significant reductions in disease while changing pneumococcal population dynamics via herd immunity and serotype replacement. We performed multilocus sequence typing (MLST) on 590 pneumococcal isolates obtained during the American Indian clinical trial of PCV7, in which communities were randomized for eligible children to receive either PCV7 or a meningococcal conjugate vaccine (MCV). Sequence types (STs) were analyzed to determine the impact of the vaccine on pneumococcal population structure and to assess the possible impact of pneumococcal genetic background on vaccine effects. One hundred forty-three STs were obtained, the most frequent being ST199, the only one that included vaccine serotypes (VTs), non-vaccine-associated nonvaccine serotypes (NVA/NVTs), and vaccine-associated serotypes (VATs). Serotype replacement observed in the PCV communities was due to a diverse population of STs, most of which also existed in the MCV communities. Possible capsular switching to create novel ST associations with NVA/NVTs was detected only once. Reductions in VTs and changes in VATs in PCV communities did not show evidence of variation by ST, after accounting for lower vaccine effectiveness against serotype 19F. These observations suggest the hypothesis that the vaccine acts as a "serotype filter": its effect on a particular strain can be predicted on the basis of the serotype of the strain, with little effect of genetic background (as assessed by MLST) over and above capsule. If sustained, such patterns provide some cause for optimism that rapid evolution of PCV escape strains with drug resistance or high virulence is unlikely.

[1]  K. O'Brien,et al.  Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. , 2007, The Journal of infectious diseases.

[2]  M. Lipsitch,et al.  Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. , 2007, The Journal of infectious diseases.

[3]  K. O'Brien,et al.  Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  W. Schaffner,et al.  Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. , 2006, The New England journal of medicine.

[5]  C. Whitney,et al.  Pre- and Postvaccination Clonal Compositions of Invasive Pneumococcal Serotypes for Isolates Collected in the United States in 1999, 2001, and 2002 , 2006, Journal of Clinical Microbiology.

[6]  S. Obaro,et al.  Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial , 2005, The Lancet.

[7]  Christophe Fraser,et al.  Neutral microepidemic evolution of bacterial pathogens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. Spratt,et al.  Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. , 2004, The Journal of infectious diseases.

[9]  K. O'Brien,et al.  Immunoblot Method To Detect Streptococcus pneumoniae and Identify Multiple Serotypes from Nasopharyngeal Secretions , 2004, Journal of Clinical Microbiology.

[10]  Steven Black,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The Journal of pediatrics.

[11]  K. O'Brien,et al.  Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial , 2003, The Lancet.

[12]  B. Spratt,et al.  Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. , 2003, The Journal of infectious diseases.

[13]  Marc Lipsitch,et al.  Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States , 2003, Nature Medicine.

[14]  R. Dagan,et al.  Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. , 2002, The Journal of infectious diseases.

[15]  L H Moulton,et al.  Design of a group-randomized Streptococcus pneumoniae vaccine trial. , 2001, Controlled clinical trials.

[16]  A. Tomasz,et al.  Nomenclature of Major Antimicrobial-Resistant Clones of Streptococcus pneumoniae Defined by the Pneumococcal Molecular Epidemiology Network , 2001, Journal of Clinical Microbiology.

[17]  George M. Carlone,et al.  Evaluation of a Medium (STGG) for Transport and Optimal Recovery of Streptococcus pneumoniae from Nasopharyngeal Secretions Collected during Field Studies , 2001, Journal of Clinical Microbiology.

[18]  S. Lockhart,et al.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media. , 2001, The New England journal of medicine.

[19]  B. Spratt,et al.  Prevention of pneumococcal disease by vaccination: does serotype replacement matter? , 2000, The Lancet.

[20]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[21]  A. J. Hall,et al.  Preparation for a pneumococcal vaccine trial in The Gambia: individual or community randomisation? , 1999, Vaccine.

[22]  M. Lipsitch Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. , 1999, Emerging infectious diseases.

[23]  M. Lipsitch,et al.  Vaccination against colonizing bacteria with multiple serotypes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Gerberding,et al.  Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. , 2005, MMWR. Morbidity and mortality weekly report.